A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

NCT02223598 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

120

Enrollment

INDUSTRY

Sponsor class

Stopped MTD determined

Conditions

Lymphoid Hematological Malignancies
Relapsed and Refractory Multiple Myeloma

Interventions

DRUG: CB-5083
DRUG: Dexamethasone

Sponsor

Cleave Biosciences, Inc.